Spring Creek Capital’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

Spring Creek Capital’s Portfolio EBACW Stock Details EBACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-16,666	Closed	-$3K	–	523
2022 Q1	$3K	Hold	16,666	–	–	﹤0.01%	818
2021 Q4	$10K	Hold	16,666	–	–	﹤0.01%	667
2021 Q3	$10K	Hold	16,666	–	–	﹤0.01%	579
2021 Q2	$16K	Buy	+16,666	New	+$15.5K	﹤0.01%	558

Other funds holding EBACW

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

AGC

Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $200M AUM 23.6% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Spring Creek Capital's EBACW Position: Q2 2022 in Review

Spring Creek Capital sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q2 2022, closing a stake of 16,666 shares — an estimated $3K sold.

Spring Creek Capital first reported a position in EBACW in Q2 2021 and held it in 4 quarters. The position peaked at $16K in Q2 2021. 32 funds tracked by Wall St. Rank hold EBACW as of Q2 2022.

Spring Creek Capital reported no remaining European Biotech Acquisition Corp. Warrant position as of Q2 2022 after selling out during the quarter.
Spring Creek Capital sold 16,666 European Biotech Acquisition Corp. Warrant shares in Q2 2022, an estimated $3K.
Spring Creek Capital first reported a position in European Biotech Acquisition Corp. Warrant in Q2 2021 and held it in 4 quarters.
Spring Creek Capital's European Biotech Acquisition Corp. Warrant position peaked at $16K in Q2 2021.
32 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.